Teleflex Wattson Bipolar Temporary Pacing Guidewire Receives FDA Clearance

June 7, 2023—Teleflex Incorporated announced FDA clearance for the Wattson bipolar temporary guidewire designed specifically for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV).

According to the company, the Wattson device’s simple design offers dual functionality, supporting both valve delivery and ventricular bipolar pacing during TAVR or BAV procedures. The device’s flexible, distal, pigtail shape and multiple-electrode, bipolar design, help reduce the risk of ventricular perforation while providing confidence in capture during rapid pacing.

The company further stated that as a procedural alternative, Wattson helps avoid a range of complications, steps, and costs associated with traditional right ventricular pacing.

The company advised that the Wattson temporary pacing guidewire will enter a limited market release phase, with a full market release anticipated later this year. Teleflex featured the device at TVT: The Structural Heart Summit held June 7-10 in Phoenix, Arizona.